Top Markets
#1 PulseChain PulseChain +45.01%
#2 Glidr Glidr +20.14%
#3 Fake World Assets Fake World Assets +9.76%
#4 Ergo Ergo +9.25%
#5 eCash eCash +8.85%
#6 DeFi Kingdoms DeFi Kingdoms +8.68%
#7 Ribbita by Virtuals Ribbita by Virtuals +8.32%
#8 Meteora Meteora +8.28%
#9 Verus Coin Verus Coin +7.70%
#10 Cash Cat Cash Cat +7.22%
Coin of the day
PulseChain PulseChain
Settings
Language
ENGLISH
Currency
USD
Theme
Codex DNA, Inc. Codex DNA, Inc.

Codex DNA, Inc.

DNAY
Rank in Stocks #28192
Operating in the synthetic biology sector, Codex DNA, Inc. develops,... Operating in the synthetic biology sector, Codex DNA, Inc. develops, manufactures, and sells advanced instruments, reagents, and complementary services. Its primary customer base comprises pharmaceutical firms and academic laboratories worldwide, though it also extends its offerings to government institutions, contract research organizations, and other synthetic biology companies. The company's innovative product portfolio includes the BioXp system, designed to transform digital DNA sequences into usable synthetic DNA, alongside the intuitive BioXp portal, an online platform facilitating DNA sequence design and assembly into chosen vectors. Researchers can also access BioXp kits, which supply essential building blocks and reagents, including the proprietary Gibson Assembly brand, for specific synthetic biology applications. Further support is provided through cloud-based scripts and specialized benchtop reagents for processing products generated by the BioXp system. Moreover, Codex DNA offers Biofoundry Services, allowing clients to commission and receive endpoint-ready BioXp products like genes, clones, cell-free amplified DNA, and variant libraries, in addition to providing short oligo ligation assembly enzymatic DNA synthesis. Established in 2011 and headquartered in San Diego, California, the company rebranded as Codex DNA, Inc. in March 2020, having previously been known as SGI-DNA, Inc.
Share Price
$1.30
Last synced: 2023-01-03
Market Cap
$27.96M
Change (1 day)
8.33%
Change (1 year)
0.00%
Country
US
Trade Codex DNA, Inc. (DNAY)

Category

Healthcare
Operating Margin for Codex DNA, Inc. (DNAY)
Operating Margin as of 2026 TTM: 0.00%
According to Codex DNA, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Codex DNA, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
17.03% -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
22.03% -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
17.86% -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
21.46% -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
28.09% -
US
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.